Escalating Costs and Questionable Deals: An Investigation into South Africa’s R836m Oxygen Plant Contracts

In an unsettling revelation, documents exposed top officials from the National Department of Health (NDoH) and the Independent Development Trust (IDT), including Health Director-General Dr. Sandile Buthelezi and IDT CEO Tebogo Malaka, being intricately involved in the negotiation of dubious contracts amounting to R836 million for the installation of oxygen plants across state hospitals in South Africa. Initially forecasted to cost R216 million, the project's expenses surged by nearly 300%, under controversial circumstances.

The project, financed by the Global Fund, initially aimed to enhance healthcare by installing oxygen plants in 55 hospitals, positioning South Africa to better manage respiratory illnesses in state facilities. However, the execution led by IDT, the project's managing agency, took several questionable turns. It was found that the agency, despite clear directives in the initial plan which was signed in August 2022, adjusted specs—amplifying costs substantially.

Bulkeng, the primary contractor chosen by IDT, landed a R428-million deal, despite documented failures to comply with multiple original criteria, including essential stipulations from the South African Health Products Regulatory Authority (SAHPRA) and Construction Industry Development Board (CIDB) grading requirements. Furthermore, a joint venture between Maziya General Trading and On Site Gas Systems International obtained another contract worth R152 million, processing these agreements with staggering anomalies and lack of transparent qualification.

The IDT's decision to alter the quantities and specifications of the required plants seemingly enabled these inflated costs. Moreover, our investigation suggests that the detailed process was possibly compromised by mismanagement or malfeasance. For example, IDT allowed Bulkeng to insert crucial documents into its bid bundle long after bids had closed and omitted mandatory SAHPRA certification from its bidding prerequisites.

It emerged that Dr. Buthelezi, already scrutinized for prior allegations involving wrongful conduct, directly influenced decisions that ignored prudent fiscal management, consulting with Malaka to override budgetary controls that escalated the project's cost to R836 million against the initially approved R216 million. Their actions not only disregarded the potential legal and auditing repercussions but also side-lined advisory opinions that recommended reevaluation of procurement protocols.

The resulting scenario presents a deeply troubling picture of governance, where due diligence and statutory requirements have given way to questionable financial decisions. This not only impacts the health sector's operational integrity but extends its consequences to public trust and the effective utilization of international funds intended for health improvements.

In light of these findings, the IDT and the NDoH were approached for comments but failed to respond, leaving significant concerns unaddressed. The IDT board has expressed its intent to manage the repercussions, ensuring those responsible face proper accountability, but the shadow of these decisions will loom large over South Africa's efforts to ensure transparent and effective health governance.